The statements below are read from SHEEL BIOTECH LIMITED’s filed results, 2 filed quarters and 6 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed Jul 18, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|
| Sales | 21.8 | 88.2 | — |
| 20.1 | 73.7 | — | |
| Operating profit | 1.77 | 14.5 | — |
| OPM % | 8.1% | 16.5% | — |
| Other income | 0.15 | 0.57 | — |
| Interest | 1.15 | 0.77 | — |
| Depreciation | 0.51 | 0.55 | — |
| Profit before tax | 0.25 | 13.8 | — |
| Tax % | 24.9% | 16.0% | — |
| Net profit | 0.19 | 11.6 | — |
| EPS (₹) | 0.00 | 6.69 | — |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
